Literature DB >> 32107984

Screening and molecular characterization of lethal mutations of human homogentisate 1, 2 dioxigenase.

Parth Sarthi Sen Gupta1,2, Rifat Nawaz Ui Islam1, Sahini Banerjee3, Arnab Nayek1, Malay Kumar Rana2, Amal Kumar Bandyopadhyay1.   

Abstract

Alkaptonuria (AKU) is an autosomal recessive disorder, which is caused by a site-specific mutation(s) and thus, impaired the function of Homogentisate-1, 2-dioxygenase (HGD), an essential enzyme for the catabolism of phenylalanine and tyrosine. Among frameshift, intronic, splice-site and missense mutations, the latter has been the most common form of genetic variations for the disease. How do the acquired mutations in HGD correlate with the disease? Systematic staged-screening of some sixty-five mutations, which are known to have a relation with the disease, by GVGD, SIFT, SNAP, PANTHER, SDM, PHD-SNP, Meta-SNP, Pmut and Mutpred methods, showed that mutations, W60G, A122D and V300G are potentially related with the severity of AKU. Detailed analyses on molecular docking and molecular dynamics simulation (MDS) of these mutants against the wild-type HGD reveal the loss of structural and molecular dynamic properties of the enzyme. Further, the observed conformational flexibility in mutants at targeted peptide segments seems to have a relation with the impairment of the function of HGD. Taken together, the study involves a designed computational methodology to analyse the disease-associated nsSNPs for AKU, the knowledge of which seems to have potential applications in drug therapies for the disease in particular and other similar systems in general.Communicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  AKU; HGD; MD simulations; PCA; molecular docking; mutations

Mesh:

Substances:

Year:  2020        PMID: 32107984     DOI: 10.1080/07391102.2020.1736158

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  1 in total

1.  Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.

Authors:  Abhik Kumar Ray; Parth Sarthi Sen Gupta; Saroj Kumar Panda; Satyaranjan Biswal; Uddipan Bhattacharya; Malay Kumar Rana
Journal:  Comput Biol Med       Date:  2021-12-29       Impact factor: 4.589

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.